Efficacy and Safety of MYL ‐1501D Versus Insulin Glargine in Patients With Type 2 Diabetes After 24 Weeks: Results of the Phase 3 INSTRIDE 2 Study

Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.

Source: Diabetes, Obesity and Metabolism - August 16, 2018 Category: Endocrinology Authors: Thomas C. Blevins MD , Abhijit Barve MD, PhD , Bin Sun , Yaron Raiter MD , Patrick Aubonnet , Rafael Muniz MD , Sandeep Athalye MD , Michael Ankersen PhD, MBA Source Type: research